Aprindine-induced polymorphous ventricular tachycardia.
Five cases of aprindine-induced polymorphous ventricular tachycardia (torsade de pointes) are presented. In four cases, polymorphous ventricular tachycardia appeared after the oral administration of 400 mg of aprindine. One patient had mild hypokalemia at the time of polymorphous ventricular tachycardia so that a direct cause and effect relation between the drug and the tachycardia cannot be established. All five patients manifested Q-T prolongation and recurrent syncope due to polymorphous ventricular tachycardia. In all five, polymorphous ventricular tachycardia subsided once administration of aprindine was discontinued.
D000368:Aged; D001073:Aprindine / Q000009:adverse effects* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004562:Electrocardiography; D005260:Female; D006801:Humans; D007192:Indenes / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D013575:Syncope / Q000139:chemically induced; D013610:Tachycardia / Q000139:chemically induced*
D007192:Indenes; D001073:Aprindine